MedTrace Logo

Effect of rEPO in FGF23 in ESRD Patients

NCT03803514 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2020-05-27

No results posted yet for this study

Summary

Objective: To evaluate the effects of recombinant Erythropoietin (rEPO) in plasma levels of Fibroblast Growth Factor 23 (FGF23) in End-Stage Renal Disease (ESRD) patients in hemodialysis.

Method: Prospective cohort of ESRD patients in HD, where patients with or without rEPO therapy were compared. Measurements of plasma FGF23 were performed at baseline and during the complete study. Demographic, clinical and laboratory data will be obtained.

Follow-up period: 12 weeks.

Conditions

  • Anemia
  • Chronic Kidney Diseases

Interventions

DRUG

Recombinant EPO

Beta-epoetin (Recormon, Roche). Dosage was performed according to current recommendations.

Sponsors & Collaborators

  • University of Chile

    lead OTHER

Principal Investigators

  • Luis Michea, MD PhD · University of Chile

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-15
Primary Completion
2019-03-31
Completion
2019-10-20

Countries

  • Chile

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03803514 on ClinicalTrials.gov